Sorafenib is effective in the treatment of pulmonary veno-occlusive disease

Masaharu Kataoka, Ryoji Yanagisawa, Keiichi Fukuda, Hideaki Yoshino, Toru Satoh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The present study is the first report of the effectiveness of sorafenib in the treatment of pulmonary veno-occlusive disease (PVOD). A 66-year-old woman with PVOD was started on sorafenib. After 3 months of treatment with a maximum dosage of 400 mg/day sorafenib, there was an improvement in the patient's New York Heart Association (NYHA) functional class from IV to III. However, because of severe painful eruptions as a side effect of sorafenib, the patient stopped sorafenib and was started on imatinib instead. This treatment resulted in a worsening of the patient's NYHA class from III to IV, so sorafenib was restarted at a reduced dosage of 300 mg/day. The resumption of sorafenib was associated with clinical improvement, specifically NYHA class from IV to II and hemodynamic amelioration, and tolerable eruptions. In conclusion, sorafenib may be a potential therapeutic strategy for the treatment of PVOD.

Original languageEnglish
Pages (from-to)172-174
Number of pages3
JournalCardiology (Switzerland)
Volume123
Issue number3
DOIs
Publication statusPublished - 2012 Nov

Fingerprint

Pulmonary Veno-Occlusive Disease
Therapeutics
sorafenib
Hemodynamics

Keywords

  • Hypertension
  • Imatinib
  • Pulmonary veno-occlusive disease
  • Side effect
  • Sorafenib

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Sorafenib is effective in the treatment of pulmonary veno-occlusive disease. / Kataoka, Masaharu; Yanagisawa, Ryoji; Fukuda, Keiichi; Yoshino, Hideaki; Satoh, Toru.

In: Cardiology (Switzerland), Vol. 123, No. 3, 11.2012, p. 172-174.

Research output: Contribution to journalArticle

Kataoka, Masaharu ; Yanagisawa, Ryoji ; Fukuda, Keiichi ; Yoshino, Hideaki ; Satoh, Toru. / Sorafenib is effective in the treatment of pulmonary veno-occlusive disease. In: Cardiology (Switzerland). 2012 ; Vol. 123, No. 3. pp. 172-174.
@article{a00b61d82bdf4b9081d621f3993d830c,
title = "Sorafenib is effective in the treatment of pulmonary veno-occlusive disease",
abstract = "The present study is the first report of the effectiveness of sorafenib in the treatment of pulmonary veno-occlusive disease (PVOD). A 66-year-old woman with PVOD was started on sorafenib. After 3 months of treatment with a maximum dosage of 400 mg/day sorafenib, there was an improvement in the patient's New York Heart Association (NYHA) functional class from IV to III. However, because of severe painful eruptions as a side effect of sorafenib, the patient stopped sorafenib and was started on imatinib instead. This treatment resulted in a worsening of the patient's NYHA class from III to IV, so sorafenib was restarted at a reduced dosage of 300 mg/day. The resumption of sorafenib was associated with clinical improvement, specifically NYHA class from IV to II and hemodynamic amelioration, and tolerable eruptions. In conclusion, sorafenib may be a potential therapeutic strategy for the treatment of PVOD.",
keywords = "Hypertension, Imatinib, Pulmonary veno-occlusive disease, Side effect, Sorafenib",
author = "Masaharu Kataoka and Ryoji Yanagisawa and Keiichi Fukuda and Hideaki Yoshino and Toru Satoh",
year = "2012",
month = "11",
doi = "10.1159/000342787",
language = "English",
volume = "123",
pages = "172--174",
journal = "Cardiology (Switzerland)",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Sorafenib is effective in the treatment of pulmonary veno-occlusive disease

AU - Kataoka, Masaharu

AU - Yanagisawa, Ryoji

AU - Fukuda, Keiichi

AU - Yoshino, Hideaki

AU - Satoh, Toru

PY - 2012/11

Y1 - 2012/11

N2 - The present study is the first report of the effectiveness of sorafenib in the treatment of pulmonary veno-occlusive disease (PVOD). A 66-year-old woman with PVOD was started on sorafenib. After 3 months of treatment with a maximum dosage of 400 mg/day sorafenib, there was an improvement in the patient's New York Heart Association (NYHA) functional class from IV to III. However, because of severe painful eruptions as a side effect of sorafenib, the patient stopped sorafenib and was started on imatinib instead. This treatment resulted in a worsening of the patient's NYHA class from III to IV, so sorafenib was restarted at a reduced dosage of 300 mg/day. The resumption of sorafenib was associated with clinical improvement, specifically NYHA class from IV to II and hemodynamic amelioration, and tolerable eruptions. In conclusion, sorafenib may be a potential therapeutic strategy for the treatment of PVOD.

AB - The present study is the first report of the effectiveness of sorafenib in the treatment of pulmonary veno-occlusive disease (PVOD). A 66-year-old woman with PVOD was started on sorafenib. After 3 months of treatment with a maximum dosage of 400 mg/day sorafenib, there was an improvement in the patient's New York Heart Association (NYHA) functional class from IV to III. However, because of severe painful eruptions as a side effect of sorafenib, the patient stopped sorafenib and was started on imatinib instead. This treatment resulted in a worsening of the patient's NYHA class from III to IV, so sorafenib was restarted at a reduced dosage of 300 mg/day. The resumption of sorafenib was associated with clinical improvement, specifically NYHA class from IV to II and hemodynamic amelioration, and tolerable eruptions. In conclusion, sorafenib may be a potential therapeutic strategy for the treatment of PVOD.

KW - Hypertension

KW - Imatinib

KW - Pulmonary veno-occlusive disease

KW - Side effect

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84868229401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868229401&partnerID=8YFLogxK

U2 - 10.1159/000342787

DO - 10.1159/000342787

M3 - Article

C2 - 23128832

AN - SCOPUS:84868229401

VL - 123

SP - 172

EP - 174

JO - Cardiology (Switzerland)

JF - Cardiology (Switzerland)

SN - 0008-6312

IS - 3

ER -